Novan Provides SB206 Program and Business Update

  • FDA grants Type C meeting for SB206 to be held on April 1, 2020
  • Last subject completes last visit, Week 24 safety evaluation
  • Additional 12-week efficacy and safety data provided


MORRISVILLE, N.C., Feb. 06, 2020 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today provided an update on several aspects of its Phase 3 B-SIMPLE program (B-SIMPLE1 and B-SIMPLE2).